Dashboard
Manage Tickers

IDYAIDEAYA Biosciences, Inc.

Nasdaq ideayabio.com


$ 42.45 $ -0.38 (-0.89 %)    

Tuesday, 07-May-2024 14:19:00 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 440.13 $ 0.61 (0.14 %)
DIA $ 388.58 $ -0.60 (-0.15 %)
SPY $ 516.86 $ -0.70 (-0.14 %)
TLT $ 90.88 $ 0.03 (0.03 %)
GLD $ 214.16 $ -0.34 (-0.16 %)
$ 43.09
$ 42.83
$ 42.35 x 100
$ 43.27 x 100
$ 41.78 - $ 43.76
$ 18.96 - $ 47.74
435,270
na
2.48B
$ 0.83
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-20-2024 12-31-2023 10-K
2 11-07-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-07-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-15-2022 06-30-2022 10-Q
8 05-10-2022 03-31-2022 10-Q
9 03-17-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-10-2021 06-30-2021 10-Q
12 05-10-2021 03-31-2021 10-Q
13 03-23-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 08-12-2020 06-30-2020 10-Q
16 05-12-2020 03-31-2020 10-Q
17 03-24-2020 12-31-2019 10-K
18 11-13-2019 09-30-2019 10-Q
19 08-12-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ideaya-biosciences-says-9414m-of-cash-cash-equivalents-and-marketable-securities-as-of-march-end-anticipated-to-fund-operations-into-2028
IDEAYA Biosciences Says $941.4M Of Cash, C...
05/07/2024 10:14:54

ideaya-biosciences-q1-2024-gaap-eps-053-inline
IDEAYA Biosciences Q1 2024 GAAP EPS $(0.53...
05/07/2024 10:13:34

IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(0.53) per share which met the analyst consensus estimate.

ideaya-biosciences-announces-asco-2024-oral-presentation-for-darovasertib-in-neoadjuvant-uveal-melanoma-phase-2-investigator-sponsored-study
IDEAYA Biosciences Announces ASCO 2024 Ora...
04/24/2024 14:06:11

Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024, at 9:51 AM CDTThe abstract summary will be available on Thur...

ideaya-biosciences-has-selected-move-forward-phase-2-expansion-dose-for-ide397-monotherapy-in-mtap-deletion-squamous-non-small-cell-lung-cancer-based-on-the-adverse-event-profile-and-preliminary-clinical-efficacy
IDEAYA Biosciences Has Selected Move-Forwa...
04/22/2024 10:02:20

Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile an...

citigroup-maintains-buy-on-ideaya-biosciences-raises-price-target-to-60
Citigroup Maintains Buy on IDEAYA Bioscien...
03/21/2024 16:17:10

Citigroup analyst Yigal Nochomovitz maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $...

Core News & Articles
Ideaya Biosciences Has Entered Into A Clin...
03/12/2024 10:11:45

demystifying-ideaya-biosciences-insights-from-6-analyst-reviews
Demystifying IDEAYA Biosciences: Insights ...
03/08/2024 20:00:32

btig-initiates-coverage-on-ideaya-biosciences-with-buy-rating-announces-price-target-of-55
BTIG Initiates Coverage On IDEAYA Bioscien...
03/08/2024 14:15:08

BTIG analyst Justin Zelin initiates coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Buy rating and announces Price Targe...

the-analyst-verdict-ideaya-biosciences-in-the-eyes-of-6-experts
The Analyst Verdict: IDEAYA Biosciences In...
02/21/2024 16:01:05

rbc-capital-maintains-outperform-on-ideaya-biosciences-raises-price-target-to-53
RBC Capital Maintains Outperform on IDEAYA...
02/21/2024 15:20:13

RBC Capital analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target f...

recap-ideaya-biosciences-q4-earnings
Recap: IDEAYA Biosciences Q4 Earnings
02/20/2024 21:45:16

ideaya-biosciences-cash-balance-as-of-december-31-2023-of-6326m-supplemented-by-net-proceeds-of-3423m-from-january-2024-atm-offerings-expected-to-fund-operations-into-2028
IDEAYA Biosciences' Cash Balance As Of Dec...
02/20/2024 11:03:45

ideaya-biosciences-q4-eps-052-misses-047-estimate-sales-392m-miss-884m-estimate
IDEAYA Biosciences Q4 EPS $(0.52) Misses $...
02/20/2024 11:02:28

IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of ...

the-analyst-verdict-ideaya-biosciences-in-the-eyes-of-8-experts
The Analyst Verdict: IDEAYA Biosciences In...
01/26/2024 15:00:56

goldman-sachs-maintains-buy-on-ideaya-biosciences-raises-price-target-to-53
Goldman Sachs Maintains Buy on IDEAYA Bios...
01/26/2024 14:35:49

Goldman Sachs analyst Corinne Jenkins maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from...

goldman-sachs-maintains-buy-rating-for-ideaya-biosciences-heres-what-you-need-to-know
Goldman Sachs Maintains Buy Rating for IDE...
01/25/2024 17:00:12

goldman-sachs-maintains-buy-on-ideaya-biosciences-raises-price-target-to-53
Goldman Sachs Maintains Buy on IDEAYA Bios...
01/25/2024 14:09:17

Goldman Sachs analyst Corinne Jenkins maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from...

announced-late-friday-on-january-19-2024-ideaya-biosciences-entered-into-an-open-market-sales-agreement-with-jefferies-under-which-the-company-may-offer-and-sell-shares-of-its-common-stock-with-aggregate-gross-proceeds-of-up-to-350m
Announced Late Friday: On January 19, 2024...
01/20/2024 15:10:33

-8-K

ideaya-biosciences-said-from-jan-4-to-jan-11-sold-46m-shares-for-net-proceeds-of-1589m-under-at-the-market-offering-pursuant-to-june-2023-agreement
Ideaya Biosciences Said From Jan 4 To Jan ...
01/12/2024 11:16:37

-8-K

critical-insights-from-ideaya-biosciences-analyst-ratings-what-you-need-to-know
Critical Insights From IDEAYA Biosciences ...
01/10/2024 17:01:17

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION